Oral drugs are designated as orange dots, and blue designates the injectable treatments
RV-8451, differentiated oral, muscle-preserving GLP-1 candidate for obesity Recent Highlights: In February 2026, Rivus stated it was entering a pivotal year, advancing HU6 in the AMPLIFY Phase 2 MASH trial while preparing the first clinical trial for RV-8451, its muscle-preserving oral GLP-1 candidate, designed to address the muscle-loss criticism leveled at existing GLP-1 therapies
Pill You must take the pill daily, on an empty stomach, with 4 ounces of water or less
Join today to unlock a wealth of knowledge and opportunities in the dynamic world of healthcare : Get a Subscription About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations
This article explores how GLP-1 works in the body to drive these outcomes, the differences between natural GLP-1 and synthetic agonists, and how to effectively navigate treatment options for sustainable health
RAND Corporation